

# AGENDA & MEETING NOTICE

## Washington State Pharmacy and Therapeutics Committee

**Date: June 20, 2007**

**Time: 9:00 a.m. – 4:00 p.m.**

**Location: Seatac Hilton**

**17620 International Blvd.**

**Seattle, WA 98188**

9:00 a.m. – 9:05 a.m.	Welcome & Introductions	<b>Dan Lessler, M.D.</b> P&T Committee Chair
9:05 a.m. – 10:30 a.m.	Drug Class Reviews – <b>SCAN</b> <b>Skeletal Muscle Relaxants</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> <b>Antiemetics</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> <b>Triptans</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> <b>Calcium Channel Blockers</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> <b>Ace Inhibitors</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	<b>OHSU EPC Staff</b> <b>Tracy Dana</b> <i>Stakeholders</i> <b>Kim Peterson</b> <i>Stakeholders</i> <b>Kim Peterson</b> <i>Stakeholders</i> <b>Kim Peterson</b> <i>Stakeholders</i> <b>Susan Carson</b> <i>Stakeholders</i> <b>P &amp; T Committee</b>
10:30 a.m. – 10:45 a.m.	Break	All
10:45 a.m. – 11:15 a.m.	Drug Class Review – <b>Update</b> <b>Anti-Platelets</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	OHSU EPC Staff <b>Marian McDonagh</b> <i>Stakeholders</i> P & T Committee
11:15 a.m. – 12:00 p.m.	Drug Class Review – <b>Update</b> <b>Newer Sedative Hypnotics</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	OHSU EPC Staff <b>Susan Carson</b> <i>Stakeholders</i> P & T Committee
12:00 p.m. – 1:00 p.m.	Lunch – <i>On your own</i>	All
1:00 p.m. – 2:30 p.m.	Drug Class Review – <b>New</b> <b>Drugs to treat Hepatitis C</b> <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	OHSU EPC Staff <b>Roger Chou</b> <i>Stakeholders</i> P & T Committee
2:30 p.m. – 2:45 p.m.	Break  <b>Drug Utilization Review on Page 2 of Agenda</b>	All

## AGENDA & MEETING NOTICE

2:45 p.m. – 4:00 p.m.

### Drug Utilization Review

- **Erythropoiesis Stimulating Agents**

- 1) Background: *The FDA and CMS have issued alerts to warn about excessive doses and off-label use of Epogen, Procrit, and Aranesp and potential cardiovascular morbidity.*
- 2) Today's Presentation: *The drug manufacturers have been working with HRSA and UMP. Criteria for appropriate use will be presented.*
- 3) Expected Outcome: *Approval of appropriate use criteria for Erythropoiesis Stimulating Agents*

**Amgen, Ortho Biotech,  
Elena Meeker, Pharm D,  
Siri Childs, Pharm D**

- **ADHD Update**

- 1) Background: *HRSA's ADHD second opinion program is one year old.*
- 2) Today's Presentation: *Dr. Thompson will present the status of the program and current outcome data*
- 3) Expected Outcome: *Informational*

**Jeffery Thompson, MD,  
Medical Director, HRSA**

4:00 p.m.

### Adjourn

### Additional Information

**Special notes:**

If you are a person with a disability and need a reasonable accommodation or have questions, please call Regina Chacón at (206) 521-2027.